No Data
Zai Lab Shares Are Trading Higher on Possible Continued Strength After the Company Announced Yesterday That It Will Present New Data for Oncology Candidates at the Upcoming Annual 2025 American Association For Cancer Research. Additionally, Cantor...
Domestic Innovative Drugs are once again surging towards overseas markets! Concept stocks have responded with a significant increase. Is the external authorization model the optimal choice?
① As of the time of publication, the Hang Seng Innovative Drugs Index has risen over 5%, with multiple Innovative Drugs concept stocks experiencing double-digit gains; ② In recent days, Jiangsu Hengrui Pharmaceuticals, Hepo Pharmaceutical, UNITED LAB, and other Biotech companies have issued announcements about "going abroad"; ③ Northeast Securities stated that top MNCs recognize the R&D capabilities of Chinese local companies and are more willing to assign high valuations.
Zai Lab Announced That New Data From Internally Developed, Next-generation Oncology Candidates Will Be Presented During Poster Sessions At The Upcoming American Association For Cancer Research (Aacr) Annual Meeting 2025 Taking Place April 25-30, 2025...
WUXI BIO's net income decline narrowed to 1.3%, with North America accounting for more than half of the revenue | Interpretations
In 2024, revenue is projected to be 18.675 billion yuan, an increase of 9.6% year-on-year, with a net income of 3.356 billion yuan, a decrease of 1.3% compared to last year. Revenue from North America reached 10.696 billion yuan, growing by 32.48% compared to 2023, accounting for 57.3% of total revenue.
Bull market sentiment? The WuXi group drives the Sector to explode, high position funds are still trapped, and Fund managers predict that the Innovative Drugs market will last throughout the year.
① The WuXi system has driven a significant rise in the pharmaceutical Sector, the Innovative Drugs bull has arrived; ② Feedback from fund investors: the Fund has rebounded, but has not returned to the original investment; ③ Investors are most concerned about whether the market can continue.
WuXi AppTec GAAP EPS of RMB3.22, Revenue of RMB39.24B; Initiates 2025 Outlook